Literature DB >> 17215375

A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection.

Ying Huang1, Huiying Yang, Brian B Borg, Xiaowen Su, Shannon L Rhodes, Kai Yang, Xiaomei Tong, George Tang, Charles D Howell, Hugo R Rosen, Chloe L Thio, David L Thomas, Harvey J Alter, Ronda K Sapp, T Jake Liang.   

Abstract

Cytokine polymorphisms are associated with disease outcome and interferon (IFN) treatment response in hepatitis C virus (HCV) infection. We genotyped eight SNPs spanning the entire IFN-gamma gene in two cohorts and assessed the association between those polymorphisms and treatment response or spontaneous viral clearance. The first cohort was composed of 284 chronically HCV-infected patients who had received IFN-alpha-based therapy and the second was 251 i.v. drug users who had either spontaneously cleared HCV or become chronically infected. A SNP variant located in the proximal IFN-gamma promoter region next to the binding motif of heat shock transcription factor (HSF), -764G, was significantly associated with sustained virological response [P = 0.01, odds ratio (OR) = 2.66 [corrected] (confidence interval 1.3-5.6)[corrected]]. The association was independently significant in multiple logistic regression (P = 0.04) along with race, viral titer, and genotype. This variant was also significantly associated with spontaneous recovery [P = 0.04, OR = 3.51 (1.0-12.5)] in the second cohort. Functional analyses show that the G allele confers a two- to three-fold higher promoter activity and stronger binding affinity to HSF1 than the C allele. Our study suggests that the IFN-gamma promoter SNP -764G/C is functionally important in determining viral clearance and treatment response in HCV-infected patients and may be used as a genetic marker to predict sustained virological response in HCV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215375      PMCID: PMC1783426          DOI: 10.1073/pnas.0609954104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  A new statistical method for haplotype reconstruction from population data.

Authors:  M Stephens; N J Smith; P Donnelly
Journal:  Am J Hum Genet       Date:  2001-03-09       Impact factor: 11.025

Review 2.  Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond.

Authors:  E M Brunt
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

Review 3.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

4.  The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Authors:  D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

5.  Polymorphisms of the human IFNG gene noncoding regions.

Authors:  J H Bream; M Carrington; S O'Toole; M Dean; B Gerrard; H D Shin; D Kosack; W Modi; H A Young; M W Smith
Journal:  Immunogenetics       Date:  2000-01       Impact factor: 2.846

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection.

Authors:  S Barrett; M Collins; C Kenny; E Ryan; C O Keane; J Crowe
Journal:  J Med Virol       Date:  2003-10       Impact factor: 2.327

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee.

Authors:  David J Woollard; Arash Grakoui; Naglaa H Shoukry; Krishna K Murthy; Katherine J Campbell; Christopher M Walker
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

10.  Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs.

Authors:  Michael Frese; Verena Schwärzle; Kerstin Barth; Nicole Krieger; Volker Lohmann; Sabine Mihm; Otto Haller; Ralf Bartenschlager
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

View more
  45 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Host genetic basis for hepatitis C virus clearance: a role for blood collection centers.

Authors:  Suganya Selvarajah; Leslie H Tobler; Graham Simmons; Michael P Busch
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

3.  Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus.

Authors:  Timothy L Mosbruger; Priya Duggal; James J Goedert; Gregory D Kirk; W Keith Hoots; Leslie H Tobler; Michael Busch; Marion G Peters; Hugo R Rosen; David L Thomas; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

4.  Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.

Authors:  Raymond T Chung; Michael Gale; Stephen J Polyak; Stanley M Lemon; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

5.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

6.  Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.

Authors:  Cassandra B Jabara; Fengyu Hu; Katie R Mollan; Sara E Williford; Prema Menezes; Yan Yang; Joseph J Eron; Michael W Fried; Michael G Hudgens; Corbin D Jones; Ronald Swanstrom; Stanley M Lemon
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  The Magnitude of IFN-γ Responses Is Fine-Tuned by DNA Architecture and the Non-coding Transcript of Ifng-as1.

Authors:  Franziska Petermann; Aleksandra Pękowska; Catrina A Johnson; Dragana Jankovic; Han-Yu Shih; Kan Jiang; William H Hudson; Stephen R Brooks; Hong-Wei Sun; Alejandro V Villarino; Chen Yao; Kentner Singleton; Rama S Akondy; Yuka Kanno; Alan Sher; Rafael Casellas; Rafi Ahmed; John J O'Shea
Journal:  Mol Cell       Date:  2019-07-31       Impact factor: 17.970

8.  Genetic markers of IgG influence the outcome of infection with hepatitis C virus.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Yuqun Luo; Yuping Wu; Robert C Elston; David L Thomas; Hugo R Rosen; James J Goedert
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

Review 9.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

10.  Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.

Authors:  Ping An; Chloe L Thio; Gregory D Kirk; Sharyne Donfield; James J Goedert; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.